Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.

Three hundred patients with symptomatic, locally advanced or metastatic NSCLC not requiring immediate radiotherapy were enrolled into this randomized multicentre trial comparing gemcitabine + BSC vs BSC alone. Patients allocated gemcitabine received 1000 mg/m2 on days 1, 8 and 15 of a 28-day cycle,...

Full description

Bibliographic Details
Main Authors: Anderson, H, Hopwood, P, Stephens, R, Thatcher, N, Cottier, B, Nicholson, M, Milroy, R, Maughan, T, Falk, S, Bond, MG, Burt, P, Connolly, C, McIllmurray, M, Carmichael, J
Format: Journal article
Language:English
Published: 2000

Similar Items